Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer
For years Fluorouracil was the established treatment for pancreatic cancer with median
survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in
comparison to Fluorouracil a significant better clinical benefit.
But after progression of the disease under a palliative first-line therapy there is no
established second line therapy for pancreatic cancer.
So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in
patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of
a palliative first line therapy to get a reasonable second line concept.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
12/2009 and end of the study 12/2010
Thomas Seufferlein, Prof. Dr.
Universitätsklinikum Halle / Klinik für Innere Medizin I
Germany: Federal Institute for Drugs and Medical Devices